Diabetic cardiomyopathy: The case for a role of fructose in disease etiology

Diabetes

Volumn 65, Issue 12, 2016, Pages 3521-3528

  Delbridge, Lea M D ^a   Benson, Vicky L ^b   Ritchie, Rebecca H ^c   Mellor, Kimberley M ^a,b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FRUCTOKINASE; FRUCTOSE; GLUCOSE; HEXOSE; N ACETYLGLUCOSAMINE;

ACYLATION; BLOOD LEVEL; CARDIAC MUSCLE CELL; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIET; FRUCTOSE METABOLISM; GLUCOSE TRANSPORT; GLYCATION; GLYCOLYSIS; HEART FAILURE; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; SUGAR INTAKE; ANIMAL; BLOOD; CARDIAC MUSCLE; DIABETIC CARDIOMYOPATHIES; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DIABETIC CARDIOMYOPATHIES; FRUCTOSE; GLYCOLYSIS; HUMANS; INSULIN RESISTANCE; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS;

EID: 85000501807     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0682     Document Type: Review

References (68)

1. Dhingra R, Sullivan L, Jacques PF, et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middleaged adults in the community. Circulation 2007;116:480-488.
2. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB. Sugarsweetened beverages and risk of metabolic syndrome and type 2 diabetes: A meta-Analysis. Diabetes Care 2010;33:2477-2483.
3. DiNicolantonio JJ, O'Keefe JH, Lucan SC. Added fructose: A principal driver of type 2 diabetes mellitus and its consequences. Mayo Clin Proc 2015;90:372-381.
4. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013;62:3307-3315.
5. Mellor KM, Ritchie RH, Davidoff AJ, Delbridge LM. Elevated dietary sugar and the heart: Experimental models and myocardial remodeling. Can J Physiol Pharmacol 2010;88:525-540.
6. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115:3213-3223.
7. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 2016;12:144-153.
8. Jia G, Aroor AR, Martinez-Lemus LA, Sowers JR. Overnutrition, mTOR signaling, and cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 2014;307:R1198-R1206.
9. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660-671.
10. Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr 2009;139:1228S-1235S.
11. Lanaspa MA, Ishimoto T, Li N, et al. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun 2013;4:2434.
12. Lyssiotis CA, Cantley LC. Metabolic syndrome: F stands for fructose and fat. Nature 2013;502:181-182.
13. Rippe JM, Angelopoulos TJ. Fructose-containing sugars and cardiovascular disease. Adv Nutr 2015;6:430-439.
14. Stanhope KL, Medici V, Bremer AA, et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr 2015;101:1144-1154.
15. Angelopoulos TJ, Lowndes J, Sinnett S, Rippe JM. Fructose containing sugars do not raise blood pressure or uric acid at normal levels of human consumption. J Clin Hypertens (Greenwich) 2015;17:87-94.
16. Malik VS, Popkin BM, Bray GA, Després JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010;121:1356-1364.
17. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A meta-Analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015;3:356-366.
18. Castagno D, Baird-Gunning J, Jhund PS, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37, 229 patient meta-Analysis. Am Heart J 2011;162:938-948.e2.
19. Mellor KM, Bell JR, Young MJ, Ritchie RH, Delbridge LM. Myocardial autophagy activation and suppressed survival signaling is associated with insulin resistance in fructose-fed mice. J Mol Cell Cardiol 2011;50:1035-1043.
20. Cheng SM, Cheng YJ, Wu LY, et al. Activated apoptotic and anti-survival effects on rat hearts with fructose induced metabolic syndrome. Cell Biochem Funct 2014;32:133-141.
21. Perret P, Slimani L, Briat A, et al. Assessment of insulin resistance in fructose-fed rats with 125I-6-deoxy-6-iodo-D-glucose, a new tracer of glucose transport. Eur J Nucl Med Mol Imaging 2007;34:734-744.
22. Huang JP, Cheng ML, Wang CH, Shiao MS, Chen JK, Hung LM. Highfructose and high-fat feeding correspondingly lead to the development of lysoPCassociated apoptotic cardiomyopathy and adrenergic signaling-related cardiac hypertrophy. Int J Cardiol 2016;215:65-76.
23. Mellor KM, Ritchie RH, Delbridge LM. Reactive oxygen species and insulinresistant cardiomyopathy. Clin Exp Pharmacol Physiol 2010;37:222-228.
24. Lou PH, Lucchinetti E, Zhang L, et al. Loss of Intralipid® - but not sevoflurane- mediated cardioprotection in early type-2 diabetic hearts of fructose-fed rats: importance of ROS signaling. PLoS One 2014;9:e104971.
25. Mellor K, Ritchie RH, Meredith G, Woodman OL, Morris MJ, Delbridge LM. High-fructose diet elevates myocardial superoxide generation in mice in the absence of cardiac hypertrophy. Nutrition 2010;26:842-848.
26. Morel S, Berthonneche C, Tanguy S, et al. Early pre-diabetic state alters adaptation of myocardial glucose metabolism during ischemia in rats. Mol Cell Biochem 2005;272:9-17.
27. Jordan JE, Simandle SA, Tulbert CD, Busija DW, Miller AW. Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 2003;307:1007-1011.
28. Joyeux-Faure M, Rossini E, Ribuot C, Faure P. Fructose-fed rat hearts are protected against ischemia-reperfusion injury. Exp Biol Med (Maywood) 2006; 231:456-462.
29. Mellor KM, Reichelt ME, Delbridge LM. Autophagy anomalies in the diabetic myocardium. Autophagy 2011;7:1263-1267.
30. Mellor KM, Bell JR, Ritchie RH, Delbridge LM. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol 2013;40: 56-61.
31. Mellor KM, Reichelt ME, Delbridge LM. Autophagic predisposition in the insulin resistant diabetic heart. Life Sci 2013;92:616-620.
32. Chang KC, Liang JT, Tseng CD, et al. Aminoguanidine prevents fructoseinduced deterioration in left ventricular-Arterial coupling in Wistar rats. Br J Pharmacol 2007;151:341-346.
33. Mellor KM, Wendt IR, Ritchie RH, Delbridge LM. Fructose diet treatment in mice induces fundamental disturbance of cardiomyocyte Ca2+ handling and myofilament responsiveness. Am J Physiol Heart Circ Physiol 2012;302:H964-H972.
34. Sommese L, Valverde CA, Blanco P, et al. Ryanodine receptor phosphorylation by CaMKII promotes spontaneous Ca(2+) release events in a rodent model of early stage diabetes: The arrhythmogenic substrate. Int J Cardiol 2016;202: 394-406.
35. Kawasaki T, Akanuma H, Yamanouchi T. Increased fructose concentrations in blood and urine in patients with diabetes. Diabetes Care 2002;25:353-357.
36. Mellor KM, Bell JR, Wendt IR, Davidoff AJ, Ritchie RH, Delbridge LM. Fructose modulates cardiomyocyte excitation-contraction coupling and Ca2? handling in vitro. PLoS One 2011;6:e25204.
37. Mirtschink P, Krishnan J, Grimm F, et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature 2015;522:444-449.
38. Jia G, Aroor AR, Whaley-Connell AT, Sowers JR. Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep 2014;16:434.
39. Lanaspa MA, Ishimoto T, Cicerchi C, et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol 2014;25:2526-2538.
40. Kashiwagi A, Obata T, Suzaki M, et al. Increase in cardiac muscle fructose content in streptozotocin-induced diabetic rats. Metabolism 1992;41:1041-1046.
41. Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr 1993;58 (Suppl.):754S-765S.
42. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012;298:229-317.
43. McLarty JL, Marsh SA, Chatham JC. Post-Translational protein modification by O-linked N-Acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci 2013;92:621-627.
44. Lauzier B, Vaillant F, Merlen C, et al. Metabolic effects of glutamine on the heart: Anaplerosis versus the hexosamine biosynthetic pathway. J Mol Cell Cardiol 2013;55:92-100.
45. Ruiz M, Gélinas R, Vaillant F, Lauzier B, Des Rosiers C. Metabolic tracing using stable isotope-labeled substrates and mass spectrometry in the perfused mouse heart. Methods Enzymol 2015;561:107-147.
46. Marsh SA, Collins HE, Chatham JC. Protein O-GlcNAcylation and cardiovascular (patho)physiology. J Biol Chem 2014;289:34449-34456.
47. Hu Y, Belke D, Suarez J, et al. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 2005;96:1006-1013.
48. Belke DD. Swim-exercised mice show a decreased level of protein O-GlcNAcylation and expression of O-GlcNAc transferase in heart. J Appl Physiol (1985) 2011;111:157-162.
49. Erickson JR, Pereira L, Wang L, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 2013;502:372-376.
50. Medrano A, García-Gil N, Ramió L, et al. Hexose-specificity of hexokinase and ADP-dependence of pyruvate kinase play important roles in the control of monosaccharide utilization in freshly diluted boar spermatozoa. Mol Reprod Dev 2006;73:1179-1194.
51. Hirahatake KM, Meissen JK, Fiehn O, Adams SH. Comparative effects of fructose and glucose on lipogenic gene expression and intermediary metabolism in HepG2 liver cells. PLoS One 2011;6:e26583.
52. Hecker PA, Mapanga RF, Kimar CP, et al. Effects of glucose-6-phosphate dehydrogenase deficiency on the metabolic and cardiac responses to obesogenic or high-fructose diets. Am J Physiol Endocrinol Metab 2012;303:E959-E972.
53. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003;92:785-792.
54. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008;117:43-51.
55. Bidasee KR, Nallani K, Yu Y, et al. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 2003;52:1825-1836.
56. Bidasee KR, Zhang Y, Shao CH, et al. Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 2004;53:463-473.
57. Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: A mechanistic perspective. Curr Med Chem 2007;14:1653-1671.
58. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated nonenzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 2004;20:369-382.
59. Hou X, Hu Z, Xu H, et al. Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway. Cardiovasc Diabetol 2014;13:78.
60. Yan D, Luo X, Li Y, et al. Effects of advanced glycation end products on calcium handling in cardiomyocytes. Cardiology 2014;129:75-83.
61. Liu J, Masurekar MR, Vatner DE, et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003;285:H2587-H2591.
62. Suárez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J Biol Chem 1989;264:3674-3679.
63. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981;213:222-224.
64. McPherson JD, Shilton BH, Walton DJ. Role of fructose in glycation and cross-linking of proteins. Biochemistry 1988;27:1901-1907.
65. Takeuchi M, Iwaki M, Takino J, et al. Immunological detection of fructosederived advanced glycation end-products. Lab Invest 2010;90:1117-1127.
66. Ferrington DA, Krainev AG, Bigelow DJ. Altered turnover of calcium regulatory proteins of the sarcoplasmic reticulum in aged skeletal muscle. J Biol Chem 1998;273:5885-5891.
67. Shimura M, Minamisawa S, Takeshima H, et al. Sarcalumenin alleviates stress-induced cardiac dysfunction by improving Ca2+ handling of the sarcoplasmic reticulum. Cardiovasc Res 2008;77:362-370.
68. Sakai M, Oimomi M, Kasuga M. Experimental studies on the role of fructose in the development of diabetic complications. Kobe J Med Sci 2002;48:125-136.